NEW YORK – Sebia and Metafora Biosystems announced on Thursday that they have entered a strategic partnership to develop a portfolio of diagnostic tests for Metafora's technology platform.
Financial and other terms of the deal were not disclosed. With the agreement, Sebia's parent company Sphinx acquired a minority share in Metafora.
Metafora's single-cell diagnostic platform is powered by artificial intelligence to detect cellular metabolism anomalies. The partnership will focus on the development of new analytical methods, particularly in hematology, to support informed therapeutic decisions, the companies said in a statement.
Jean-Marc Chermette, Sebia's chairman and CEO, said the companies will initially focus on applications in multiple myeloma and then expand to other therapeutic areas.
"Sebia’s investment enables us to accelerate our R&D programs and prepare for commercial launches between now and 2023," Metafora CEO and cofounder Vincent Petit said in a statement. "We look forward to collaborating with Sebia’s team and learning from their wealth of expertise in diagnostics to accelerate our development."
Paris-based Metafora also provides artificial intelligence software to support the deployment of flow cytometry tests and a solution to increase the efficacy of cell therapies.
It intends to launch its first diagnostic test, METAglut1, in Europe next year. The automated flow cytometry test detects De Vivo disease, a neurometabolic disorder associated with a deficiency of the glucose transporter type 1 protein.